Suppression of immune complex-induced inflammation by the chemotactic factor inactivator.

The Journal of clinical investigation ·Vol. 59 ·No. 5 ·1977-05-00 ·Pages 951-8

Johnson KJ, Anderson TP, Ward PA

Abstract

Small amounts (10(-10) mol) of purified human chemotactic factor inactivator (CFI) suppress leukocytic infiltration, permeability changes, and hemorrhage associated with acute immune complex-induced injury in rats. The reversed passive dermal Arthus reaction and acute immune complex-induced alveolitis in rats have served as the model systems of inflammation. The mechanism of inhibition does not appear to relate to interference with formation and deposition of immune complexes, or with fixation of complement in vitro or iv vivo. Human CFI inhibits in vitro the chemotactic activity generated in complement-activated rat serum. The inhibitory effects of human CFI are not seen if it is first heat inactivated. The data provide the first direct support for the conclusion that CFI has anti-inflammatory activity.

MeSH Terms

Aminopeptidases/therapeutic use Animals Antigen-Antibody Complex Arthus Reaction/drug therapy,pathology Chemotaxis, Leukocyte Inflammation/drug therapy Male Rats Serum Albumin, Bovine/immunology Skin/pathology

Chemicals

Antigen-Antibody Complex chemotactic factor inactivator Serum Albumin, Bovine Aminopeptidases

Authors & Affiliations

3 authors, click to expand affiliations / ORCID

Johnson K J

Anderson T P

Ward P A

References (16)

16 references, click to expand

Defective regulation of chemotaxis in cirrhosis.
J Lab Clin Med. 1975 Apr;85(4):621-30 PMID: 1120929
Changes in C3 metabolism during protozoan infection (Babesia rodhaini) in rats.
J Immunol. 1976 May;116(5):1284-8 PMID: 1270796
The role of polymorphonuclear leukocytes in the initiation and cessation of the Arthus vasculitis.
J Exp Med. 1959 Sep 1;110:481-94 PMID: 13810816
BOUND COMPLEMENT AND IMMUNOLOGIC INJURY OF BLOOD VESSELS.
J Exp Med. 1965 Feb 1;121:215-34 PMID: 14264268
Chemotactic factor inactivator in normal human serum.
J Clin Invest. 1973 May;52(5):1200-6 PMID: 4121701
Immunologic tissue injury mediated by neutrophilic leukocytes.
Adv Immunol. 1968;9:97-162 PMID: 4236490
Biologic role of complement products. Complement-derived leukotactic activity extractable from lesions of immunologic vasculitis.
J Immunol. 1972 May;108(5):1137-45 PMID: 4260453
Acute immunologic pulmonary alveolitis.
J Clin Invest. 1974 Aug;54(2):349-57 PMID: 4277008
Two distinct chemotactic factor inactivators in human serum.
J Immunol. 1975 Feb;114(2 pt 2):843-7 PMID: 46254
Characterization of serum inhibitors of neutrophil chemotaxis associated with anergy.
J Immunol. 1974 Jul;113(1):189-200 PMID: 4832308
Defective regulation of inflammatory mediators in Hodgkin's disease. Supernormal levels of chemotactic-factor inactivator.
N Engl J Med. 1974 Jan 10;290(2):76-80 PMID: 4855544
C5 chemotactic fragments produced by an enzyme in lysosomal granules of neutrophils.
J Immunol. 1970 Mar;104(3):535-43 PMID: 4985169
The chemosuppression of chemotaxis.
J Exp Med. 1966 Aug 1;124(2):209-26 PMID: 5950689
Characterization of the protease activity in the chemotactic factor inactivator.
J Clin Invest. 1976 Jul;58(1):123-9 PMID: 6489
Leukotactic dystunction in sarcoidosis.
Ann Intern Med. 1976 Apr;84(4):414-9 PMID: 769631
Defective leukotaxis in patients with lepromatous leprosy.
J Lab Clin Med. 1976 Jun;87(6):1025-32 PMID: 778311

Article Info

Journal

The Journal of clinical investigation

Abbr.

J Clin Invest

ISSN

0021-9738

DOI

10.1172/JCI108717

Published

1977-05-00

Pages

951-8

Language

English

Region

United States

NLM ID

7802877

PMCID

PMC372303

Subset

External Links

PubMed source DOI: 10.1172/JCI108717 PMC Full Text View journal details

Analysis Services

Suppression of immune complex-induced inflammation by the chemotactic factor inactivator.

Contact

WeChat Official Account